CN1960974A - 烷基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途 - Google Patents

烷基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途 Download PDF

Info

Publication number
CN1960974A
CN1960974A CNA2005800172558A CN200580017255A CN1960974A CN 1960974 A CN1960974 A CN 1960974A CN A2005800172558 A CNA2005800172558 A CN A2005800172558A CN 200580017255 A CN200580017255 A CN 200580017255A CN 1960974 A CN1960974 A CN 1960974A
Authority
CN
China
Prior art keywords
tetramethyl
chloro
piperidines
phenyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800172558A
Other languages
English (en)
Chinese (zh)
Inventor
D·彼得斯
G·M·奥尔森
E·O·尼尔森
J·谢尔-克吕格尔
B·L·埃里克森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of CN1960974A publication Critical patent/CN1960974A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2005800172558A 2004-06-18 2005-06-14 烷基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途 Pending CN1960974A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400961 2004-06-18
DKPA200400961 2004-06-18

Publications (1)

Publication Number Publication Date
CN1960974A true CN1960974A (zh) 2007-05-09

Family

ID=37311739

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800172558A Pending CN1960974A (zh) 2004-06-18 2005-06-14 烷基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途

Country Status (9)

Country Link
US (3) US7547788B2 (enExample)
EP (1) EP1761493A2 (enExample)
JP (1) JP2008502651A (enExample)
CN (1) CN1960974A (enExample)
AR (1) AR050341A1 (enExample)
CA (1) CA2570075A1 (enExample)
MX (1) MXPA06013917A (enExample)
TW (1) TW200604173A (enExample)
WO (1) WO2005123679A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570075A1 (en) * 2004-06-18 2005-12-29 Neurosearch A/S Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1896415A1 (en) * 2005-06-08 2008-03-12 NeuroSearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20110046179A1 (en) * 2006-08-30 2011-02-24 Eriksen Birgitte L Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MX2010009581A (es) * 2008-03-05 2010-09-30 Neurosearch As Derivados novedosos de 4-bencidriloxi-tetraalquil-piperidina y su uso como inhibidores de reabsorcion del neurotransmisor de monoamina.
US8546576B2 (en) * 2008-06-06 2013-10-01 Sk Biopharmaceuticals Co., Ltd. 3 or 4-substituted piperidine compounds
US20170204060A1 (en) * 2014-05-21 2017-07-20 Solvay Specialty Polymers Usa, Llc Piperidine-based stabilizers and polymers end-capped with the same
EP3145911B1 (en) * 2014-05-21 2020-07-08 Solvay Specialty Polymers USA, L.L.C. Stabilizer compounds
MX374426B (es) 2015-01-22 2025-03-06 Evonik Operations Gmbh Sintesis de compuestos de triacetonadiamina mediante procedimiento de aminacion reductora de triacetonadiamina y derivados de los mismos.
MX2016000701A (es) 2015-01-22 2016-11-24 Evonik Degussa Gmbh Proceso para preparar un compuesto de triacetonamina n-metil sustituida.
DE102016212378A1 (de) 2016-07-07 2018-01-11 Evonik Degussa Gmbh Synthese von Triacetondiaminverbindungen durch reduktive Aminierung ausgehend von Triacetondiamin und dessen Derivaten
DE102016212379A1 (de) 2016-07-07 2018-01-11 Evonik Degussa Gmbh Verfahren zur Herstellung einer N-methylsubstituierten Triacetonaminverbindung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3684765A (en) * 1970-01-08 1972-08-15 Sankyo Co Stabilization of synthetic polymers
GB1411782A (en) 1972-02-24 1975-10-29 Wyeth John & Brother Ltd Piperidine derivatives
US3907813A (en) * 1973-09-11 1975-09-23 Janssen Pharmaceutica Nv Stereoisomeric forms of 4-anilino-3-methyl piperidines
US3923992A (en) * 1974-05-23 1975-12-02 Univ Mississippi Analgetic composition and method of use
FR2361880A1 (fr) * 1976-04-29 1978-03-17 Science Union & Cie Nouvelles 4-amino piperidines, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant
DE3218645A1 (de) * 1982-05-18 1983-11-24 Hoechst Ag, 6230 Frankfurt Fluoranverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbbilder in kopiersystemen
JPS63206757A (ja) 1987-02-23 1988-08-26 Mitsubishi Paper Mills Ltd 電子写真感光体
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US4939161A (en) * 1989-05-12 1990-07-03 Boc, Inc. Analgesic N-aryl-N-[1-substituted-3,5-dimethyl-4-piperidinyl]amides
WO1991003511A1 (en) 1989-09-09 1991-03-21 Sandoz Ltd Synthetic polyamides and their salts
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
JPH11348418A (ja) 1998-04-08 1999-12-21 Seiko Epson Corp 記録媒体および記録液
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
WO2002089803A1 (fr) * 2001-05-07 2002-11-14 Sankyo Company, Limited Composition d'ionophorese
DE60331762D1 (de) 2002-11-01 2010-04-29 Neurosearch As Neue piperidinderivate und deren verwendung als monoaminneurotransmitter-wiederaufnahmehemmer
CA2570075A1 (en) * 2004-06-18 2005-12-29 Neurosearch A/S Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
US7547788B2 (en) 2009-06-16
AR050341A1 (es) 2006-10-18
JP2008502651A (ja) 2008-01-31
WO2005123679A2 (en) 2005-12-29
US7915419B2 (en) 2011-03-29
US20070167487A1 (en) 2007-07-19
WO2005123679A3 (en) 2006-03-02
TW200604173A (en) 2006-02-01
US20110086880A1 (en) 2011-04-14
US20090215820A1 (en) 2009-08-27
MXPA06013917A (es) 2007-03-07
CA2570075A1 (en) 2005-12-29
EP1761493A2 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
CN1077574C (zh) 托烷衍生物,其制备和应用
CN1021323C (zh) 新的抗抑郁剂的制法
CN1189170C (zh) 噻吩基唑基烷氧基乙胺,它们的制备以及它们作为药物的应用
CN1269805C (zh) 4－(苯基－哌嗪基－甲基)－苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用
CN1039996C (zh) N－取代氮杂双环庚烷衍生物及其用途
CN1043763C (zh) 莨菪烷衍生物及其制备方法和应用
CN1636980A (zh) 二肽腈组织蛋白酶k抑制剂
CN1039491C (zh) 四氢咔唑化合物及其制备方法和应用
CN1269719A (zh) 调节性活力的芳酰基哌嗪
CN1659141A (zh) 作为5－ht6－受体调节剂用于治疗cns－病症的1－磺酰基－4－氨基烷氧基吲哚衍生物
CN1104017A (zh) 取代的(芳烷氧基苄基)氨基丙酰胺衍生物及其制备方法
CN1705654A (zh) 使用对映体富集的西酞普兰去甲基和二去甲基代谢产物治疗抑郁症以及其它中枢神经病症的方法
CN86103227A (zh) 制备2-吡咯烷酮衍生物的方法
CN1082959C (zh) 取代苯并噻吩基哌嗪、作为药物的用途及制备方法
CN1466567A (zh) 取代的1-氨基丁-3-醇衍生物
CN86108051A (zh) 非芳香族氟烯丙胺mao抑制剂
JP2008502651A (ja) モノアミン神経伝達物質再取込み阻害剤としての、新規アルキル置換ピペリジン誘導体及びその使用
CN1107469A (zh) 环胺衍生物
CN1543964A (zh) 积雪草酸及其衍生物在制备抗抑郁药物中的应用
CN1121713A (zh) 丝氨酸衍生物
CN1147461C (zh) 3-氨基-3-芳基丙-1-醇衍生物、其制备及用途
CN1500487A (zh) 左西替利嗪伪麻黄碱复方口服制剂及制备方法
CN1054418A (zh) 对于和涉及(s)-去甲氟苯氧丙胺的改进
CN1466573A (zh) 5-苯基苄胺化合物、其制备方法以及其合成中间体
CN1196053A (zh) 治疗疼痛用的新杂环化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20070509